*New Data* Leveraging Non-Animal Models to Improve Donor Selection & Product Reproducibility

  • Uncovering new insights into how donor cell properties influence final product performance, even when engineered identically
  • Applying non-animal systems to identify optimal starting materials for iPSC and peripheral blood-derived therapies, in line with new FDA guidance
  • Improving product consistency by understanding therapeutic activity at the source and moving beyond the limitations of traditional animal models